Rare Disease Trial, Recruiting NCT07362225 Sponsor: MPN Research Foundation Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT07362225
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older when you sign up.
  • You must have been diagnosed with a type of blood condition called a myeloproliferative neoplasm (MPN), which includes: polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), secondary myelofibrosis (post-ET or post-PV MF), pre-fibrotic primary myelofibrosis (pre-PMF), MPN-unclassifiable, MPN in accelerated phase, MPN in blast phase, post-MPN acute myeloid leukemia (AML), or MDS/MPN overlap syndrome — as confirmed by current medical guidelines.
  • People who were originally diagnosed with one of these conditions and have since had a stem cell or bone marrow transplant may also be eligible.
  • You must be able to give your agreement to take part, either yourself or through a legally appointed representative (such as a guardian).
  • You must be willing to share your health information, including medical records and lab results.
  • You must be willing to fill out regular surveys about your symptoms and how you are feeling.

Who may not be able to join:

  • People under 18 years of age are not eligible.
  • If you are unable to give consent yourself and do not have a legally appointed representative to do so on your behalf, you would not be eligible.
  • If you are currently taking part in another clinical trial that involves a treatment or intervention, you may not be able to join if it would interfere with this study (confirm with trial site).
  • If the study team determines that taking part in the registry would not be safe or practical for you for any reason, you may not be eligible (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center

Phone: 847-449-5307

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
MPN Research Foundation
Registry
ClinicalTrials.gov
Start date
26 September 2025
Est. completion
8 September 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time to Disease Progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov